File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: A randomized trial

TitleThe use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: A randomized trial
Authors
KeywordsCervical priming
Misoprostol
Oral
Vaginal
Issue Date1999
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 1999, v. 14 n. 8, p. 2139-2142 How to Cite?
AbstractMisoprostol is effective for cervical priming prior to vacuum aspiration for first trimester termination of pregnancy. Previous studies showed that the oral route was more acceptable to patients but there were higher incidences of side-effects when compared with the vaginal route. This study is to determine the optimal dosage and route of administration of misoprostol for pre-operative cervical dilatation. A double-blind, randomized trial was undertaken for 225 nulliparous women with 8-12 weeks amenorrhoea. They were randomly assigned to groups given 0 (placebo), 200 or 4 μg oral or vaginal misoprostol 3 h Drier to vacuum aspiration. In misoprostol-treated groups the baseline cervical dilatation was significantly increased when compared with the placebo group; the effect was dose-related in the oral but not in the vaginal group. The cumulative force and blood loss was significantly decreased in the misoprostol-treated groups. The incidences of side-effects were more frequent in misoprostol groups but were not related to the route and dosage of medication. The duration of procedure, incidences of post-operative complications, the duration of post-operative bleeding and the interval to the first period were similar in the five treatment groups. We conclude that a 3 h pre-treatment interval is effective for both oral and vaginal routes. When given orally, 400 μg is more effective than 200 μg. The efficacy was otherwise similar when compared with the vaginal route. We recommend 400 μg oral misoprostol 3 h prior to vacuum aspiration for cervical dilatation.
Persistent Identifierhttp://hdl.handle.net/10722/87087
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNgai, SWen_HK
dc.contributor.authorChan, YMen_HK
dc.contributor.authorTang, OSen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2010-09-06T09:25:09Z-
dc.date.available2010-09-06T09:25:09Z-
dc.date.issued1999en_HK
dc.identifier.citationHuman Reproduction, 1999, v. 14 n. 8, p. 2139-2142en_HK
dc.identifier.issn0268-1161en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87087-
dc.description.abstractMisoprostol is effective for cervical priming prior to vacuum aspiration for first trimester termination of pregnancy. Previous studies showed that the oral route was more acceptable to patients but there were higher incidences of side-effects when compared with the vaginal route. This study is to determine the optimal dosage and route of administration of misoprostol for pre-operative cervical dilatation. A double-blind, randomized trial was undertaken for 225 nulliparous women with 8-12 weeks amenorrhoea. They were randomly assigned to groups given 0 (placebo), 200 or 4 μg oral or vaginal misoprostol 3 h Drier to vacuum aspiration. In misoprostol-treated groups the baseline cervical dilatation was significantly increased when compared with the placebo group; the effect was dose-related in the oral but not in the vaginal group. The cumulative force and blood loss was significantly decreased in the misoprostol-treated groups. The incidences of side-effects were more frequent in misoprostol groups but were not related to the route and dosage of medication. The duration of procedure, incidences of post-operative complications, the duration of post-operative bleeding and the interval to the first period were similar in the five treatment groups. We conclude that a 3 h pre-treatment interval is effective for both oral and vaginal routes. When given orally, 400 μg is more effective than 200 μg. The efficacy was otherwise similar when compared with the vaginal route. We recommend 400 μg oral misoprostol 3 h prior to vacuum aspiration for cervical dilatation.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_HK
dc.relation.ispartofHuman Reproductionen_HK
dc.rightsHuman Reproduction. Copyright © Oxford University Press.en_HK
dc.subjectCervical primingen_HK
dc.subjectMisoprostolen_HK
dc.subjectOralen_HK
dc.subjectVaginalen_HK
dc.titleThe use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: A randomized trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0268-1161&volume=14&issue=8&spage=2139&epage=2142&date=1999&atitle=The+use+of+misoprostol+for+pre-operative+cervical+dilatation+prior+to+vacuum+aspiration+:+a+randomized+trialen_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/humrep/14.8.2139en_HK
dc.identifier.pmid10438440en_HK
dc.identifier.scopuseid_2-s2.0-0032800182en_HK
dc.identifier.hkuros44438en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032800182&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue8en_HK
dc.identifier.spage2139en_HK
dc.identifier.epage2142en_HK
dc.identifier.isiWOS:000081959700043-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridNgai, SW=7006074214en_HK
dc.identifier.scopusauthoridChan, YM=7403676661en_HK
dc.identifier.scopusauthoridTang, OS=7006723402en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats